Overview

EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Enterome

Treatments:

Nivolumab